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Title: The Effectiveness of Dexmedetomidine in Patients Receiving Spinal Anesthesia.
Background: A failed subarachnoid block due to prolonged surgical duration can be
difficult and frustrating issue for anesthesia providers. The overall failure rate for SABs
has been reported to be 0.6%, with about one-fourth of all failed SABs attributed to
prolonged surgical times. Dexmedetomidine has been shown to extend the duration of
subarachnoid block.
Purpose: To conduct an extensive literature review of dexmedetomidine efficacy as an
adjunct to prolonging duration subarachnoid anesthesia.
Process: A systematic literature review was conducted using PubMed, CINAHL,
Cochrane and Access Medicine for articles that related to the use of intravenous
dexmedetomidine during subarachnoid anesthesia. The literature was then integrated to
develop evidence-based recommendations for use of intravenous dexmedetomidine in
patients receiving subarachnoid anesthesia.
Results: Administration of intravenous dexmedetomidine with or without bolus dose has
been shown to be safe and effective at prolonging the duration of subarachnoid
anesthesia.
Implications: Anesthesia providers must weigh the risk and benefits when using
intravenous dexmedetomidine as an adjunct to subarachnoid anesthesia. Use and dosage
of bolus dose should be made on a case-by-case basis due to bradycardia concerns.
Dexmedetomidine has the added benefit of providing titratable intraoperative sedation
without causing significant respiratory depression.
Keywords: dexmedetomidine, spinal, subarachnoid block
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The Effectiveness of Dexmedetomidine in Patients Receiving Spinal Anesthesia.
Spinal anesthesia can be traced back to the late 1800s with the work of James
Leonard Corning followed by August Karl Gustav Bier. The basis of these experiments is
given to William Halstead and Richard Hall, who had published work demonstrating the
utilization of cocaine for local and regional anesthesia. (Looseley, 2009, para. 3)
Corning first conducted experiments that involved the injection of a cocaine
solution into the vertebral spaces of a young dog. He discovered that within five minutes
there was a loss of coordination followed by weakness and then eventually anesthesia of
the dog’s hindquarters that resolved in four hours. Following this discovery, Corning next
experimented on a human subject in which he injected a cocaine solution into the
T11/T12 interspinous space. With no initial changes he repeated the injection and found
that after 10 minutes the patient could feel changes in his legs and there was a significant
disruption to the sensitivity of a pinprick and electrical current to the lumbar region down
with no motor deficit. Corning did not indicate any finding of cerebrospinal fluid (CSF),
so he most likely was injecting into the epidural space. Fourteen years later in 1898, the
pioneer of spinal anesthesia Dr. August Karl Bier published the first reports of a
subarachnoid block (SAB), which was used successfully and the primary anesthetic for a
surgical procedure. Dr. Bier’s remarkable breakthrough is similar to the process we use
today. (Looseley, 2009, para. 3-4)
Spinal anesthesia is a very safe, reliable, and effective anesthesia technique with
reliable results that can be used in alone, in conjunction with general anesthesia, epidural
and IV anesthetic (Nagelhout & Plaus, 2013; Butterworth, Mackey, Morgan & Wasnick,
2013). The advantages of using neuraxial (spinal and epidural) anesthesia include
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decreased nausea, vomiting, urinary retention, reduced opioid need, and greater mental
alertness compared to patients who had general anesthesia alone (Nagelhout & Plaus,
2013). There is evidence that neuraxial anesthesia blunts the body’s stress response to
surgery; provides preemptive anesthesia; and decreases intraoperative blood loss,
postoperative thromboembolic events and ileus. Additionally, spinal anesthesia increases
patency of vascular grafts, and improves respiratory function and cardiac stability, and
improves outcomes in high-risk patients (Nagelhout & Plaus, 2013; Butterworth et al.,
2013). The subarachnoid block (SAB) is commonly used to provide anesthesia for
operations below the umbilicus such as orthopedic procedures involving the hips and
below, caesarean delivery, endovascular aortic aneurysm repair, urological procedures,
hernia repair, and some gynecological procedures (Schug, Saunders, Kurowski, & Paech,
2006).
One disadvantage of a SAB is the inability to extend the duration of the anesthetic
intraoperatively due to the needs of a prolonged surgical procedure (Johnson & Pugh,
2016). The overall failure rate for SABs has been reported to be 0.6%, with
approximately one-fourth of all failed SABs attributed to prolonged surgical times
(Guglielmo, Pignataro, Difiore, Lanza, & Mercadante, 2010). Research has shown that
dexmedetomidine can extend the duration of the SAB (Johnson & Pugh, 2016). Patients
who receive a SAB most often desire sedation, which dexmedetomidine can provide in
conjunction with extending the duration of the block (Johnson & Pugh, 2016).
Purpose
A major disadvantage of spinal anesthesia is unexpected prolongation of the
surgical procedure. The purpose of the literature review was to determine if
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dexmedetomidine was viable adjunct to spinal anesthesia and will it prolong the spinal
block. Intravenous dexmedetomidine is a possible pharmacological adjunct that could be
added to allow coverage for the extended procedure. The risk and benefits of adding
intravenous dexmedetomidine to the anesthesia plan must be addressed to each individual
patient. Use and dosage of bolus dose should be made on a case-by-case basis due to
bradycardia concerns. Dexmedetomidine has the added benefit of providing titratable
intraoperative sedation without causing significant respiratory depression over propofol.
Case Report
A 64-year-old, 90 kilogram (kg), 175 centimeter (cm) male presented for a right
total hip arthroplasty (RTH) due to a previous injury. Surgical history includes a
tonsillectomy as a young child. No prior issues or concerns with anesthesia were
reported. The patient’s medication regime included omeprazole for gastroesophageal
reflux disease, acetaminophen as for right hip pain, and trazadone for sleep daily. No
known drug allergies.
A pre-operative airway evaluation revealed a Mallampati classification II,
thyromental distance of greater than three fingerbreadths, intact dentition, and full neck
range of motion. Preoperative vital signs were heart rate (HR) 84/min, blood pressure
(BP) 136/84 mmHg, respiratory rate (RR) 16/min, pulse oximetry (SpO2) 98% on room
air, and temperature (T) 97.9 Fahrenheit. Physical exam found clear lung sounds, S1 and
S2 heart sounds without murmur, and bilateral extremity pulses present and equal. The
patient was considered an American Society of Anesthesiologists (ASA) physical status
level two. In the preoperative area, an 18 gauge peripheral intravenous (IV) catheter was
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inserted into the patient’s left forearm. No medications were given prior to being
transferred to operating room (OR).
Upon entering the OR suite, the patient transferred himself onto operating room
table, standard monitors were simultaneously applied which included: a finger pulse
oximeter, non-invasive blood pressure cuff on his right upper arm, and a 5-lead
electrocardiogram (EKG). Oxygen was administered at 2 liters per minute (LPM) via an
end-tidal carbon dioxide (ETCO2) sampling nasal cannula. Initial vital signs were HR
91/min, BP 141/90 mmHg, RR 18/min, SpO2 97% on 2 LPM nasal cannula. He was
given midazolam 2 milligrams (mg) IV and fentanyl 100 micrograms (mcg) IV due to
pain in his right hip and anxiety regarding the spinal placement. He was assisted to sitting
position on the side of the OR table with a chair at the side of the bed for him to rest his
feet. The circulating was nurse standing in front of the patient to assist with positioning
for spinal placement. The lumbar area was prepped in a sterile fashion, a 2 mL 1%
Lidocaine skin wheel was performed at the L3-4 region. A 25 gauge 3 ¾ inch pencil tip
spinal needle was inserted midline in the lumbar 3-4 interspace. Correct placement of the
SAB was confirmed with CSF presence; 1.7 milliliters (mL) of 0.75% bupivacaine (in
8.25% dextrose) with 0.2 mg preservative-free morphine was injected. Once the SAB
was completed, the patient was placed in the supine position and sensory loss was
assessed to dermatome level T6-T7 via sharp pinprick. The patients systolic BP
decreased from 140s to 110s and remained constant throughout the procedure.
Due to the patient exhibiting airway obstruction after his premedication of
midazolam 2 mg IV and fentanyl 100 mcg IV, dexmedetomidine was selected for IV
sedation. Dexmedetomidine was chosen due to its ability to provide sedation without
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respiratory depression. Oxygen was titrated up to 4 LPM due to the SpO2 decreasing
from 97% to 93%. A dexmedetomidine bolus was initiated at 0.5 mcg/kg over 10 min
followed by maintenance infusion of 0.5 mcg/kg/hr. A propofol bolus of 20 mg IV was
given before incision as the dexmedetomidine bolus had not yet infused; the patient was
exhibiting signs of anxiety. A single dose of glycopyrrolate 0.2 mg IV was administered
to counteract bradycardia of 50-55/min, thought to be caused by the dexmedetomidine
bolus and infusion. HR returned to 60-65/min within 5 minutes and remained stable for
the duration of the case. During the procedure, the patient required one additional dose of
propofol 20 mg IV for sedation. The remainder of the case was uneventful. The patient
remained hemodynamically stable and was able to maintain his airway throughout the
three hour and twenty minute surgical procedure with oxygen saturations greater than
94% on 4 LPM nasal cannula.
Near the conclusion of surgery and beginning of incision closure, the
dexmedetomidine infusion was discontinued, and ondansetron 4 mg IV was given for
post-operative nausea and vomiting (PONV) prophylaxis. Prior to the patient being
transferred to the post-anesthesia care unit (PACU) he was able to open his eyes and
follow commands appropriately.
Upon arrival to PACU, vitals signs were within normal limits, the patient was
following commands, answering questions, and denied any presence of pain or nausea.
Oxygen was titrated to 2 LPM with oxygen saturation at 99%.
Literature Search
Search Strategy
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The comprehensive review of literature was conducted through the University of
North Dakota (UND) Harley E. French Library of Health Sciences online library website.
Articles were obtained by the Cumulative Index to Nursing and Allied Health
(CINAHL), PubMed, Access Medicine, Cochrane databases and the American
Association of Nurse Anesthetists (AANA) journal. Key words applied to conduct this
search included: dexmedetomidine, spinal, subarachnoid block.
Research began with a search in CINAHL. It is an easy to use database that
utilizes journals from the nursing field and the 17 allied health disciplines with around
2700 journals. The first search term used was “dexmedetomidine” which returned 93
articles. The search was limited the search to English language and newer than 2012,
which returned 22. Of the 22 articles, 2 were relevant to the PICO question. My second
search was “spinal”, returning 4 articles. Between the 2 searches a total of 3 articles were
found to be relevant to the PICO question.
The next database used was PubMed. PubMed is a service of the United States
National Library of Medicine. It provides journal articles from a broader array of
specialties such as: medical, nursing, dental, health care and preclinical sciences. This
broader reach of specialties offers a greater likelihood of finding relevant articles. The
initial search of “dexmedetomidine ” returned 372 and with a 3-year limitation it was cut
down to 143. The search term “spinal” was added, which weaned the total to 28. There
were 3 articles that directly addressed the specific topic of interest. From the references I
searched the DOI numbers and found the articles on PubMed. The snowball continued
from there by continuing to look up the resources from the original paper and then the
subsequent papers from there. This search also led to the AANA journal article with a
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applicable topic. The reference section was again used to identify relevant articles. In all,
19 articles were printed for possible use in the paper.
Review of Literature
Administration of Spinal Anesthesia
The majority of subarachnoid blocks are placed in either the sitting or lateral
position on the OR table (Schwartz & Brunicardi, 2015). Positioning is dependent on the
patient’s ability to follow commands, maintain the position, pain level, desired
dermatome coverage, as well as type of OR table being used (Schwartz & Brunicardi,
2015). Before the SAB the patient is connected to the BP, EKG, and SpO2 monitors and
O2 is administered via nasal cannula. Premedication for the spinal procedure is at the
discretion of the anesthetist and is most often dependent on comorbidities and anxiety
level of the patient (Schwartz & Brunicardi, 2015). The patient’s back is cleansed with an
antiseptic solution, skin is infiltrated with local anesthetic, a 25-27 gauge spinal needle is
introduced in the lower lumbar region, and the subdural space is identified by the
presence of CSF (Sanford, 2014). The local anesthetic is injected directly into the dural
sac that surrounds the spinal cord (Sanford, 2014). The level of injection is usually below
L1 to L2, where the spinal cord ends in most adults (Nagelhout & Plaus, 2013). Local
anesthetic and addition of opioid are chosen based on the length of surgery and surgical
procedure. Once the local anesthetic is injected, the patient is placed in the supine
position for 5-10 minutes to allow for the proper spread of the local anesthetic (Sanford,
2014). During this period, hypotension and bradycardia can be induced by a
sympathectomy due to the cephalad spread of the local anesthetic (Sanford, 2014).
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Patient positioning should be maintained to allow the anesthetic block to set up properly.
Once the block has stabilized, the surgical preparation and positioning can proceed
(Sanford, 2014).
Mechanism of Action
	
  

The exact mechanism of action for subarachnoid anesthesia continues to contain

much speculation. The primary site of action for the blockade is the nerve roots within
the spinal cord (Nagelhout & Plaus, 2013). A local anesthetic is injected into the CSF,
distributing through the subarachnoid space. The spread of local anesthetic is based on
the positioning of the patient, physical/chemical properties of the drug, and
characteristics of the space in which it is to spread (Nagelhout & Plaus, 2013). When
drug concentrations reach a minimally effective concentration at the nerve root, neuronal
transmission is altered in a clinically significant way, which provides anesthesia
(Nagelhout & Plaus, 2013). “Blockade of neural transmission in the posterior nerve root
fibers interrupts somatic and visceral sensation, whereas blockade of anterior nerve root
fibers interrupts efferent motor and autonomic outflow” (Nagelhout & Plaus, 2013, p.
1073). The nerve size, length, myelination and distance from injection are all important
factors in the susceptibility of the nerve to the local anesthetic (Nagelhout & Plaus, 2013;
Butterworth et al., 2013).
Local anesthetics work by reversibly binding to the voltage-gated sodium
channels, preventing channel activation and inhibiting the sodium influx associated with
membrane depolarization (Butterworth et al., 2013). This process alters nerve
transmission with increasing drug concentrations until action potential is unable to be
generated and impulses transmitted (Butterworth et al., 2013).
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Dexmedetomidine
Mechanism of action Dexmedetomidine is a selective alpha-2 adrenergic agonist
that functions by stimulating the receptors, resulting in a decrease of catecholamine
release and sympathetic nervous system (SNS) response (Eilers & Yost, 2015).
Dexmedetomidine’s primary effects are sedation with minimal respiration depression,
anxiolysis, reduced postoperative shivering and agitation, and cardiovascular
sympatholytic actions (Nagelhout & Plaus, 2013). This drug profile makes it a useful
adjunct for sedation with spinal anesthesia.
The highly selective alpha-2 agonist with spinal anti-nociceptive (visceral and
somatic) properties produces a synergistic effect with intraspinal local anesthetics (Kalso,
Pöyhiä, & Rosenburg, 1991). The reduced noradrenergic outflow is thought to strengthen
the inhibitory nociceptive effect on the spinal cord (Samuels & Szabadi 2008). The
higher alpha-2 receptor selectivity for IV dexmedetomidine reduces the severity of
hemodynamic instability (bradycardia and hypotension) and is capable of extending the
duration of a SAB longer than clonidine (Abdallah, Abrishami, & Brull, 2013).
Dosage Standard adult dosing is 0.5-1 mcg/kg IV bolus infused over 10 minutes
followed by a maintenance infusion of 0.2-0.7 mcg/kg/hr (Nagelhout & Plaus, 2013).
Side effects Dexmedetomidine has been shown to exhibit moderate decreases in
heart rate and systemic vascular resistance, which leads to a decrease in systemic blood
pressure (Eilers & Yost, 2015). A bolus injection may produce a transient increase in
systemic blood pressure and pronounced decrease in heart rate (Eilers & Yost, 2015).
Bradycardia associated with dexmedetomidine infusion may require treatment (Eilers &
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Yost, 2015). Heart block, severe bradycardia, and asystole have been observed and may
result from unopposed vagal stimulation (Eilers & Yost, 2015).
Pharmacokinetics Dexmedetomidine has a rapid onset with a loading infusion of
approximately 10-20 minutes and duration of action post infusion of 10-30 minutes
(Nagelhout & Plaus, 2013). The elimination half-life is 2 hours (Nagelhout & Plaus,
2013). Dexmedetomidine shows linear kinetics in the dosage range of 0.2 – 0.7
mcg/kg/hr (Nagelhout & Plaus, 2013). It is highly protein bound at 94%, rapidly
metabolized by the liver, and excreted in urine and bile. Patients with severe liver
dysfunction or impaired kidney function may need a dose adjustment (Nagelhout &
Plaus, 2013).
Dexmedetomidine as Adjunct in Surgery with Spinal Anesthesia
A supraspinal mechanism of action of IV dexmedetomidine has not been clearly
defined. It is thought that when administered IV alpha-2 agonists inhibit the activity of
the locus coeruleus in the brain, leading to noradrenergic nuclei (Johnson & Pugh, 2016).
The decreased noradrenergic outflow is believed to strengthen the inhibitory nociceptive
effect on the spinal cord (Samuels & Szabadi 2008).
The two alpha-2 agonists commonly used in practice are dexmedetomidine and
clonidine. Dexmedetomidine has a higher affinity for the alpha-2 receptor versus alpha-1
when compared to clonidine, reducing the bradycardia and hypotension (Schug et al.,
2006).
According to a systematic review with meta-analysis by Abdullah, Abrishami,
and Brull (2013), IV dexmedetomidine may be an effective spinal adjunct for prolonging
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the duration of regional blockade, sedation, and postoperative analgesia in patients
receiving SAB. This systematic review contained seven randomized controlled trials
(RCTs) examining 364 subjects distributed evenly between placebo and IV
dexmedetomidine treatment groups. The outcome of primary focus was the duration of
motor and sensory block, postoperative analgesia, and adverse-related effects such as
hypotension, bradycardia, respiratory depression, and postoperative sedation (Abdallah,
et al., 2013).
The results of the Abdallah et al. (2013) review suggests that IV
dexmedetomidine in conjunction with spinal anesthesia can prolong the duration of
sensory block and to a lesser extent motor block. It was also found that IV
dexmedetomidine might delay the time to first analgesic request after spinal anesthesia.
With these effects there is a heightened risk of transient reversible bradycardia. The study
researched another alpha-2 agonist clonidine, and their findings suggest IV
dexmedetomidine produces a greater differential blockade by preferentially targeting
sensory myelinated alpha fibers over unmyelinated C fibers involved in motor
conduction. Variations among spinal and dexmedetomidine dosing make it difficult to
translate into clinical practice guidelines (Abdallah, et al., 2013). Dexmedetomidine bolus
doses varied from 0.5-1.0 mcg/kg with and without maintenance rates of 0.2-0.5 mcg/kg
over varying durations (Johnson & Pugh, 2016). It was noted that isolated boluses of 0.5
mcg/kg administered as isolated boluses significantly prolonged the anesthetic effect of
the SAB (Johnson & Pugh, 2016). Dosing of dexmedetomidine throughout the studies
was highly variable and there was a lack of standardization of assessment means for
sensory and motor block duration (Johnson & Pugh, 2016). Suggestions were made to
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study optimal dosing of dexmedetomidine and formulate standardization of evaluation
techniques (Abdallah, et al., 2013).
In 2016, the American Association of Nurse Anesthetists (AANA) Journal
conducted and published an evidence-based review, which updates the Abdallah et al.
2013 systematic review. Initially, 79 sources were narrowed to eight RCTs based on
inclusion and exclusion criteria. Within the RCTs there were 480 subjects. The RCTs
looked at the outcomes of IV dexmedetomidine administered in conjunction with a SAB.
Outcome measures included motor and sensory blockade, postoperative analgesia, and
the side effects of bradycardia and hypotension. Several limitations were noted within the
RCT, such as three studies failed to describe blinding methods, twos studies lacked
power analysis to determine sample size for outcomes measured and one study had an
underpowered base due to subject withdrawal (Johnson & Pugh, 2016).
Dexmedetomidine was dosed as either a bolus only or a bolus with maintenance
infusion (Johnson & Pugh, 2016). Among the studies, there was a variation in the start
time of the dexmedetomidine infusion (Johnson & Pugh, 2016). Two of the RCTs
neglected to administer a preload IV fluid bolus before the SAB (Johnson & Pugh, 2016).
Bupivacaine was the local anesthetic of choice, but the dose and concentration were not
disclosed in all the studies (Johnson & Pugh, 2016). The surgical procedures varied from
pelvic, lower extremity, to urological. A 2-dermatome regression (TDR) of at least 20
minutes was utilized in all eight studies to evaluate sensory block duration (Johnson &
Pugh, 2016). The Modified Bromage Scale (MBS) 0-3 scale was used to measure motor
block duration in six studies with a MBS of 0-6 in another (Johnson & Pugh, 2016).
Another study only used knee flexion to measure motor recovery (Johnson & Pugh,
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2016). The MBS scores recorded endpoints for motor recovery ranging from 0-1 and 4
(Johnson & Pugh, 2016). The observer variability, subjective measurements, patient
participation, and IV dexmedetomidine sedation may have an impact on the validity and
reliability of these findings (Johnson & Pugh, 2016). Four studies evaluated
dexmedetomidine IV with SAB’s effect on postoperative analgesia, but there were a wide
variety of assessment tools used hindering the ability to find correlations (Johnson &
Pugh, 2016). Observers noted differences with highest initial maximum sensory level
achieved by SAB (in those that reported this finding) but found that dexmedetomidine
administration before the SAB had no influence on the initial spread of spinal local
anesthetic (Johnson & Pugh, 2016). The differences in highest initial maximum sensory
level could be due to many different factors including height, weight, local anesthetic
dose and baricity, and positioning (Johnson & Pugh, 2016). The impact was determined
to be that IV dexmedetomidine prolonged the maximal duration with little effect on the
initial level of sensory blockade (Johnson & Pugh, 2016).
Pain Pathway
The primary purpose of subarachnoid anesthesia is to block transmission of
sensory, motor, and pain during surgical intervention (Nagelhout & Plaus, 2013).
Disrupting the afferent and efferent pathways is accomplished by administration of
subarachnoid local anesthetics (Nagelhout & Plaus, 2013). Depending on the area of
surgical interest, a certain level dermatome level of sensory blockade is desired
(Nagelhout & Plaus, 2013). Spinal nerves provide a particular area of cutaneous
innervation that is anatomically mapped out in dermatome levels (Nagelhout & Plaus,
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2013). A dermatome is the defined area that is innervated by the specific spinal nerves
(Nagelhout & Plaus, 2013).
According to Nagelhout and Plaus (2013), “Pain and temperature receptors in the
skin of the trunk and extremities send signals to the spinal cord via the dorsal roots of the
spinal nerves” (p. 696). The dorsal root sensory fibers terminate in the dorsal horn before
crossing over to lateral fibers (Nagelhout & Plaus, 2013). The sensory information then
ascends via the anterior spinothalamic and lateral spinothalamic tracts (Nagelhout &
Plaus, 2013). The dorsal column-medial lemniscal tract also carries afferent sensory
information with a greater degree of localization (Nagelhout & Plaus, 2013).
Motor pathways follow a descending ventral pathway that originates in the
corticospinal tract (Nagelhout & Plaus, 2013). A majority of neurons cross over to form
the lateral corticospinal tract, where they continue their descent (Nagelhout & Plaus,
2013). At each spinal cord level, fibers leave the lateral corticospinal tract to the ventral
horn gray matter where they synapse with lower motor neurons (Nagelhout & Plaus,
2013). The neurons that do not cross descend via the ventral corticospinal tract
(Nagelhout & Plaus, 2013). These neurons cross over before synapsing with lower motor
neurons within the gray matter(Nagelhout & Plaus, 2013). The axons from the lower
motor neurons travel in the spinal nerves to innervate voluntary muscle (Nagelhout &
Plaus, 2013). Local anesthetic from a SAB interrupts the pain pathways by altering the
ability of spinal nerves to generate and transmit impulses.
Conclusion
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A significant disadvantage of subarachnoid anesthesia is the inability to extend
the duration of the anesthetic intraoperatively to address the needs of prolonged surgical
procedures (Johnson & Pugh, 2016). There are several methods available to solve this
problem that include using intrathecal adjuncts, combined spinal-epidural techniques, and
higher subarachnoid local anesthetic doses. Intravenous dexmedetomidine offers a
simple, effective method for prolonging the duration of motor and sensory blockade and
postoperative analgesia with a minimal side effect profile (Johnson & Pugh, 2016).
Utilization of IV dexmedetomidine as primary subarachnoid block adjunct must be
evaluated on a case by case basis (Johnson & Pugh, 2016).
Intravenous dexmedetomidine has the additional benefit of providing sedation
during the procedure, which is often desired by most individuals receiving subarachnoid
blocks (Johnson & Pugh, 2016). Anesthesia providers should be cognizant of the
undesirable side effects associated with IV dexmedetomidine, as well as the management
of adverse reactions. Bradycardia is a common side effect related to IV
dexmedetomidine, which may be detrimental to patient depending on comorbidities.
Attachment of standard monitors and frequent monitoring should be utilized to evaluate
the tolerance of bradycardia in each patient. Bradycardia that is not tolerated should be
treated immediately. Intravenous dexmedetomidine does not cause major respiratory
depression while providing a safe, titratable level of intraoperative sedation (Venn, Hell,
& Grounds, 2000). Intravenous dexmedetomidine has shown to safely and effectively
prolong a subarachnoid block, therefore anesthesia providers should consider the use of
IV dexmedetomidine in surgical procedures that may be unexpectedly extended.
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